Search Results - "Roux, Susanne"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
  2. 2

    A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial by Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S., Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul

    Published in Annals of oncology (01-02-2022)
    “…While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with…”
    Get full text
    Journal Article
  3. 3